Assesses etoricoxib-loaded transdermal patches for treating and preventing knee osteoarthritis progression, indicating promising therapeutic effects.
Key Points
The central aim is to evaluate the effectiveness of etoricoxib nanocrystal transdermal patches in treating knee osteoarthritis and preventing symptom progression.
Prepared etoricoxib nanocrystal patches using solvent evaporation technique.
Evaluated patches for drug content, thickness, moisture uptake, and folding endurance.
Assessed in vitro drug release and skin permeation properties of patches based on various polymers.
CMC Na based patches showed the highest drug release of 73.76 ± 2.38%.
HPMC and CMC Na patches demonstrated notable skin penetration rates of 79.64 ± 1.20 μg/cm² and 44.06 ± 2.72 μg/cm², respectively.
ETX-NCs patches alleviated osteoarthritis symptoms in just 5 days and helped protect against disease progression.